Treatment with pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer: a multicenter real-world study

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are effective for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, therapies subsequent to TKI progression remain controversial, and effective treatments for TKI resistance are urgently needed. We evalu...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Yijia, Li, Wei, Jin, Nan, Cai, Dongyan, Sun, Jie, Sun, Chunxiao, Yang, Fan, Wu, Xinyu, Huang, Xiang, Wang, Biyun, Yin, Yongmei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958671/
https://www.ncbi.nlm.nih.gov/pubmed/35356262
http://dx.doi.org/10.1177/17588359221085232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8958671/
https://www.ncbi.nlm.nih.gov/pubmed/35356262
http://dx.doi.org/10.1177/17588359221085232

Ejemplares similares